Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2020-02-14 1:30 pm Sale | 13G | GLYCOMIMETICS INC GLYC | PRICE T ROWE ASSOCIATES INC | 2,134 0% | -3,460,439 (-99.94%) | View |
| 2020-02-07 4:09 pm Purchase | 13G | GLYCOMIMETICS INC GLYC | Invesco Ltd. IVZ | 4,772,724 11% | 4,467 (+0.09%) | View |
| 2020-02-05 11:45 am Sale | 13G | GLYCOMIMETICS INC GLYC | BlackRock Inc. BLK | 2,828,511 6.5% | -16,382 (-0.58%) | View |
| 2020-01-08 3:11 pm Sale | 13G | GLYCOMIMETICS INC GLYC | WELLINGTON MANAGEMENT GROUP LLP | 3,705,977 8.55% | -1,613,288 (-30.33%) | View |
| 2019-09-10 11:19 am Sale | 13G | GLYCOMIMETICS INC GLYC | FMR LLC | 1,809,900 4.19% | -4,665,254 (-72.05%) | View |
| 2019-09-09 4:44 pm Purchase | 13G | GLYCOMIMETICS INC GLYC | BIOTECHNOLOGY VALUE FUND L P | 7,361,801 17% | 2,925,000 (+65.93%) | View |
| 2019-08-15 1:09 pm Purchase | 13G | GLYCOMIMETICS INC GLYC | BIOTECHNOLOGY VALUE FUND L P | 4,436,801 10.3% | 3,939,327 (+791.87%) | View |
| 2019-08-15 12:26 pm Purchase | 13G | GLYCOMIMETICS INC GLYC | Camber Capital Management LP | 3,500,000 8.1% | 3,500,000 (New Position) | View |
| 2019-08-12 10:21 am Purchase | 13G | GLYCOMIMETICS INC GLYC | FMR LLC | 6,475,154 14.995% | 2,943,510 (+83.35%) | View |
| 2019-06-10 11:01 am Purchase | 13G | GLYCOMIMETICS INC GLYC | Invesco Ltd. IVZ | 4,768,257 11% | 4,768,257 (New Position) | View |